Dominik Ruettinger/AACR-Todd Buchanan 2025
Apr 29, 2025, 18:44
Dominik Ruettinger highlights Bayer’s oncology research strategy at AACR25
Dominik Ruettinger, SVP, Global Head of Research and Early Development Oncology at Bayer Pharmaceuticals, shared a post on LinkedIn:
“This year’s annual meeting of the American Association for Cancer Research (AACR) is held in Chicago. It was a great pleasure to provide an update on our precision drug development strategy in Oncology R&D.
Very much in line with this year’s motto of “Unifying cancer science and medicine: a continuum of innovation for impact”, it was enriching to exchange with industry peers, investors and academia. I am now looking forward to the main meeting at AACR25.
Make sure to check out some key research updates that Bayer – Pharmaceuticals and Vividion Therapeutics, Inc. will be presenting.”
Learn more about AACR25 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 29, 2025, 18:44
Apr 29, 2025, 18:33
Apr 29, 2025, 18:12
Apr 29, 2025, 18:10
Apr 29, 2025, 18:02
Apr 29, 2025, 17:47
Apr 29, 2025, 17:41
Apr 29, 2025, 17:29